Lindbrook Capital’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Lindbrook Capital’s Portfolio LABU Stock Details LABU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$152K	Buy	2,490 +1,745	+234%	+$149K	0.01%	503
2024 Q4	$67K	Buy	745 +340	+84%	+$40K	0.01%	693
2024 Q3	$52.1K	Sell	405 -38	-9%	-$4.96K	﹤0.01%	798
2024 Q2	$50.3K	Buy	443 +393	+786%	+$42.1K	﹤0.01%	795
2024 Q1	$6.64K	Buy	+50	New	+$6.53K	﹤0.01%	1770
2023 Q4	–	Sell	-3,110	Closed	-$237K	–	2756
2023 Q3	$237K	Buy	3,110 +775	+33%	+$79.5K	0.03%	284
2023 Q2	$276K	Buy	2,335 +100	+4%	+$12.5K	0.03%	260
2023 Q1	$219K	Sell	2,235 -1,000	-31%	-$136K	0.03%	297
2022 Q4	$457K	Buy	+3,235	New	+$451K	0.06%	192

Other funds holding LABU

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wolverine Trading Chicago, Illinois $139B AUM 31.83% 1-Year Est. Return

EFG

Ethos Financial Group King Of Prussia, Pennsylvania $1.5B AUM 22.75% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Lindbrook Capital's LABU Position: Q1 2025 in Review

Lindbrook Capital increased its Direxion Daily S&P Biotech Bull 3X ETF (LABU) stake by 234% in Q1 2025, buying an estimated $149K and bringing the position to 2,490 shares worth $152K. The position accounts for 0.01% of the portfolio, ranked #503.

Lindbrook Capital first reported a position in LABU in Q4 2022 and has held it in 9 quarters since. The position peaked at $457K in Q4 2022. 35 funds tracked by Wall St. Rank hold LABU as of Q1 2025.

Lindbrook Capital held 2,490 shares of Direxion Daily S&P Biotech Bull 3X ETF worth $152K as of Q1 2025.
Lindbrook Capital bought 1,745 Direxion Daily S&P Biotech Bull 3X ETF shares in Q1 2025, an estimated $149K.
Direxion Daily S&P Biotech Bull 3X ETF made up 0.01% of Lindbrook Capital's portfolio in Q1 2025, its #503 holding.
Lindbrook Capital first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q4 2022 and has held it in 9 quarters since.
Lindbrook Capital's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $457K in Q4 2022.
35 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.